Study on Biomarkers of Immune-Related Adverse Events
ConditionImmune-Related Adverse Events
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHuazhong University of Science and Technology
About this trial
1. To identify biomarkers of immune-related adverse events; 2. To develop a predictive model for immune-related adverse events.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age >18 years;
Karnofsky Performance Status (KPS) >60;
Expected to receive at least one cycle of immune checkpoint inhibitor therapy;
Expected survival >6 months.
Disqualifiers
Prior treatment with immune checkpoint inhibitors;
Active autoimmune diseases (including systemic lupus erythematosus, inflammatory bowel disease, rheumatoid arthritis, myasthenia gravis, scleroderma, etc.);
Use of systemic immunosuppressive agents within 14 days prior to enrollment (prednisone >10 mg/day or equivalent);
Inability to provide biological samples.
Trial population
patients with malignancies undergoing immunotherapy
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
440 Participants
are grouped into 1 trial groupGroup A: Patients with malignancies receiving immunotherapy
Trial outcomes
Primary outcomes
1
Immune-Related Adverse Events
Immune-Related Adverse Events
Time frame
2 yearsSecondary outcomes
1
overall survival
Time frame
5 yearsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Huazhong University of Science and Technology
Lead sponsor
Tongji Hospital
Sponsor institution
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: